Evolvulus alsinoides (dwarf morning glory)
Also called dwarf morning glory, slender dwarf morning glory, Sankhaholi, Vishnukranthi, vishnukranti, shankhpushpi (name also used for Convolvulus pluricaulis).
Best grade D across 1 graded outcome Botanical Last checked
The short answer
From 5 sourcesEvolvulus alsinoides is a small herb from Unani medicine. The only controlled human trial is a 6-week, open-label Indian study in 57 people with high blood pressure, comparing 630 mg/day of extract with ramipril; systolic pressure did not differ and diastolic pressure and IL-6 were lower with the herb. There is no placebo-controlled human evidence.
Every graded outcome on this page
1 row · line = participantsKey facts
- Only trial
- 57 adults with primary hypertension completed 42 days of 630 mg/day extract or 5 mg/day ramipril, both with a DASH diet1
- Systolic pressure
- No significant difference from ramipril (mean difference -1.88 mmHg, p = 0.203)1
- Diastolic pressure
- 2.83 mmHg lower than ramipril (p = 0.003)1
- Design limits
- Open-label, no placebo, single extract, 6 weeks1
- Animal safety
- Oral ethanol extract up to 2,000 mg/kg for 28 days caused no deaths or organ damage in mice2
What it is
Evolvulus alsinoides (dwarf morning glory) is a small creeping herb used in Unani medicine, including for heart conditions.
How it works
ProposedThe trial authors cite traditional Unani use for cardiovascular disorders and earlier preclinical and clinical work pointing to blood-pressure-lowering potential. How it might work in people is not known.1
Forms
Form
| Form | Elemental % | Absorption (human data) | GI tolerance | Studied for |
|---|---|---|---|---|
| Hydro-alcoholic extract capsules | Varies1Not applicable (whole compound or extract; no elemental fraction) | Not measured in the trial abstract.1 | No significant differences in symptoms vs ramipril; adverse events not detailed in the abstract.1 | High blood pressure |
What the human research says
Human trials only, one row per outcome. The form line shows what each trial actually tested. Grades follow our evidence-grading policy.
Trial map
1 graded outcome, largest study firstOne graded outcome so far. Blood pressure and inflammation markers in primary hypertension: a 2024 randomized trial of 57 people found mixed results.
1Blood pressure and inflammation markers in primary hypertension
Mixed · Grade D · RCT, 57 people, 2024
Adults with primary hypertension (India; 57 completed)
Dose, result and source| Outcome | Found | People | Study | Who was studied |
|---|---|---|---|---|
| Blood pressure and inflammation markers in primary hypertension | Mixed | 57 | Grade D · RCT, 2024 | Adults with primary hypertension (India; 57 completed) |
Every graded row
1 rowDGrade DBlood pressure and inflammation markers in primary hypertensionBlood pressureSimilar systolic BP to ramiprilRCT
n 57 · 2024
Mixed Versus ramipril, systolic pressure did not differ (mean difference -1.88 mmHg, p = 0.203), while diastolic pressure (-2.83 mmHg, p = 0.003) and IL-6 (p = 0.005) were lower with the extract. Symptom scores did not differ.
- Design
- RCT, n = 57, 2024
- Population
- Adults with primary hypertension (India; 57 completed)
- Form
- Hydro-alcoholic Evolvulus alsinoides extract capsules vs ramipril 5 mg, both with DASH diet advice
- Dose
- 630 mg/day
- Duration
- 42 days
- Source
- Reference 1 · PubMed 38159824 (opens PubMed)
What the numbers add up to
Each point is worked out from the data and the sources numbered on this page, with the arithmetic shown under it. It adds no new data and is not medical advice.
One trial, no placebo
All human evidence on this page is one open-label comparison with ramipril in 57 people, so it cannot separate a drug-like effect from diet change and expectation.1
Studied doses
Doses used in research, shown against the official limits. They describe the studies, not a recommendation for you.
Studied doses in research, not advice. These are amounts used in research, not personal advice. Your clinician or pharmacist can say what fits you.
Doses studied in human trials
Doses studied in human trials ranged from 630 mg/day of a dried hydro-alcoholic extract, the only dose tested, for 42 days. This is a research dose, not a recommendation.1
Interactions and safety
Published interactions only: each row cites a source. No row means none was found in our sources, not that a combination is safe.
Interactions
0 agentsNone found in our sources.
Check with what you take
Kept on this device onlyAdd what you take. We list every interaction our evidence profiles cite between Evolvulus alsinoides and your picks, and between your picks.
- Loading names…
Add a supplement or medicine you take to check it against Evolvulus alsinoides.
Starting from one medicine? The interaction checker rates how serious each pair is, on a curated list of 19 entries for 11 medicines. This cabinet has no severity rating: it lists every interaction row our supplement pages cite.
Who should be careful
4 groups- People on blood pressure medicines
- The trial compared the extract with ramipril rather than adding it; combined effects with blood pressure drugs were not studied.1
- People with diagnosed hypertension
- Evidence is a single open-label 6-week trial without placebo, which cannot show the herb can replace prescribed treatment.1
- Drug interactions
- No published drug-interaction studies were found.1
How to read the label
What to check on the Supplement Facts panel.
How to read the label
1 checksFrequently asked questions
Short answers to common questions; the numbers link to the sources below.
Common questions
5 answersDoes Evolvulus alsinoides lower blood pressure?
In one 6-week open-label trial of 57 people, 630 mg/day of extract gave similar systolic pressure to 5 mg ramipril and lower diastolic pressure. There is no placebo-controlled trial.1
Is it a memory herb?
Its extract has been tested for memory effects in mice, but no controlled human memory trial was found.3
Is it safe?
Can it be taken with blood pressure medicine?
This has not been studied. The only human trial gave the extract (630 mg/day) instead of ramipril, not alongside it, and we found no published drug-interaction studies.1
Sources
5 sources: trial abstracts, NIH fact sheets and reference databases. Numbers in the text link here.
Sources cited on this page
5 sources- 1Evaluation of the efficacy of hydro-alcoholic extract of Evolvulus alsinoides L. for the treatment of primary hypertension - A randomized controlled trial.RCT J Ethnopharmacol, 2024 · PMID 38159824
- 2In Vivo Toxicity Study of Ethanolic Extracts of Evolvulus alsinoides & Centella asiatica in Swiss Albino Mice.Animal study Open Access Maced J Med Sci, 2019 · PMID 31049083
- 3Nootropic activity of methanolic extract from Evolvulus alsinoides Linn. in mice with scopolamine-induced amnesia.Animal study Bioinformation, 2023 · PMID 38250536
- 4Convolvulus pluricaulis confers antidepressant and antioxidant effects through conserved metabolic and molecular pathways in Drosophila.Animal study iScience, 2026 · PMID 41602909
- 5A clinical study on Clitoria ternatea tea therapy to manage diabetic distress in people with type 2 diabetes.Open-label trial Avicenna J Phytomed, 2026 · PMID 42153010
What changed
Every dated change to this page: what changed, who made it and why.
Change log
2 entries| Date | Change | Who and why |
|---|---|---|
| FAQ and links | Added an FAQ on use with blood pressure medicines, page questions, and links to butterfly pea and the heart goal hub. Re-ran PubMed for Evolvulus alsinoides (all years): the 2024 hypertension trial is still the only human trial; other records are lab, animal and plant studies. LactMed, LiverTox and NCCIH have no entry, so pregnancy, breastfeeding, liver and interaction notes stay as 'not studied'. | Writer: Kymata Health EditorialTrigger: A–Z audit against docs/supplements/AUDIT-STANDARD.md |
| all | Initial editorial evidence review (first draft). Every PMID checked against NCBI E-utilities esummary (titles and years taken from the record, none retracted) and the abstract read for each cited row. Studied doses are reported as research doses, not dosing advice. | Writer: Kymata Health EditorialTrigger: new page |
Supplement & Nutrient Encyclopedia. Educational information only; it is not medical advice and does not replace a clinician. Dietary supplements are not intended to diagnose, treat, cure or prevent any disease. Statements about supplements have not been evaluated by the FDA.